Q-omics provides the consensus-scored NPY2R profile across patient tissues and cancer cell-line models. NPY2R expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NPY2R is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, NPY2R RNA expression shows 9,676 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, COAD, and THYM as cancer lineages where NPY2R shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPY2R — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPY2R survival associations across molecular data types. NPY2R RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPY2R RNA expression–survival associations across cancer types. High NPY2R expression shows unfavorable associations in KICH, CESC, CHOL, LGG and SCLC, but favorable associations in LUAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for NPY2R RNA expression.
This table summarizes NPY2R tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NPY2R. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPY2R shows lower tumor expression in COAD, KIRC, READ, BRCA, STAD and KIRP. The COAD box plot shows higher NPY2R RNA expression in normal versus tumor tissue (log2 FC = −0.989, t-test p < 0.001).
This table shows molecular features associated with NPY2R in patient tissues and cancer cell lines. In patient samples, NPY2R shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPY2R RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
